期刊文献+

“可能切除的胰腺癌”新辅助治疗研究进展 被引量:4

原文传递
导出
摘要 胰腺癌在美国肿瘤相关死亡中居第4位[1],在我国居第7位[2],5年生存率低于5%.仅有15% ~ 20%的患者为可切除胰腺癌,通过手术达到R0切除(肿瘤切缘阴性)后,5年生存率为15% ~ 20% [3-5].随着外科学的发展,约有1/3的局部进展期胰腺癌从不可切除胰腺癌中被分离出来,称为“可能切除(borderline resectable)的胰腺癌”.新辅助治疗可使这部分患者的肿瘤进展停滞甚至降期,从而提高肿瘤切缘阴性率,延长生存时间.本文对“可能切除的胰腺癌”的新辅助治疗进展作一综述,以期提高临床医师对“可能切除的胰腺癌”新辅助治疗的重视.
出处 《中华外科杂志》 CAS CSCD 北大核心 2014年第6期464-466,共3页 Chinese Journal of Surgery
  • 相关文献

参考文献29

  • 1Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300. 被引量:1
  • 2曾红梅,郑荣寿,张思维,赵平,赫捷,陈万青.1989-2008年中国恶性肿瘤死亡趋势分析[J].中华肿瘤杂志,2012,34(7):525-531. 被引量:100
  • 3Vincent A,Herman J,Schulick R,et al.Pancreatic cancer[J].Lancet,2011,378(9791):607-620. 被引量:1
  • 4Varadhachary GR,Tamm EP,Abbruzzese JL,et al.Borderline resectable pancreatic cancer:definitions,management,and role of preoperative therapy[J].Ann Surg Oncol,2006,13 (8):1035-1046. 被引量:1
  • 5Springett GM,Hoffe SE.Borderline resectable pancreatic cancer:on the edge of survival[J].Cancer Control,2008,15 (4):295-307. 被引量:1
  • 6Callery MP,Chang KJ,Fishman EK,et al.Pretreatment assessment of resectable and borderline resectable pancreatic cancer:expert consensus statement[J].Ann Surg Onco1,2009,16:1727-1733. 被引量:1
  • 7Talamonti MS,Small W Jr,Mulcahy MF,et al.A multi-institutional phase Ⅱ trial of preoperative full-dose gemcitabine and concurrentradiation for patients with potentially resectable pancreatic carcinoma[J].Ann Surg Oncol,2006,13 (2):150-158. 被引量:1
  • 8Taniguchi CM,Murphy JD,Eclov N,et al.Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2013,85 (4):1090-1095. 被引量:1
  • 9Cetin V,Piperdi B,Bathini V,et al.A phase Ⅱ trial of cetuximab,gemcitabine,5-fluorouracil,and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma[J].Gastrointest Cancer Res,2013,6(4 Suppl 1):S2-9. 被引量:1
  • 10Homma Y,Taniguchi K,Murakami T,et al.Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma[J].Ann Surg Oncol,2013,21 (2):670-676. 被引量:1

二级参考文献8

  • 1赫捷,赵平,陈万青.2011中国肿瘤登记年报.北京:军事医学科学出版社,2011:20-23. 被引量:4
  • 2Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents, Vol. IX, IARC Scientific Publications No. 160. Lyon : IARC, 2007 : 67-71. 被引量:1
  • 3Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon: IARC, 1994:35-49. 被引量:1
  • 4Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC Technical Report No. 42. Lyon : IARC, 2005 : 11-39. 被引量:1
  • 5Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 2000,19: 335-351. 被引量:1
  • 6贺宇彤,候俊,陈志峰,等.河北省磁县近三十年食管鳞癌发病死亡趋势分析.中华流行病学杂志,2007,29:764-767. 被引量:1
  • 7Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer, 2012,118:2338-2366. 被引量:1
  • 8陈万青,张思维.中国肿瘤登记的代表性研究[J].中国肿瘤,2008,17(10):832-835. 被引量:12

共引文献99

同被引文献48

  • 1Lemke J,Schafer D,Sander S,et al.Survival and prognostic factors in pancreatic and ampullary cancer[J].Anticancer Res,2014,34(6):3011-3020. 被引量:1
  • 2Tschoep-Lechner KE,Milani V,Berger F,et al.Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer[J].Int J Hyperthermia,2013,29(1):8-16. 被引量:1
  • 3Roviello F,Caruso S,Neri A,et al.Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:overview and rationale[J].Eur J Surg Oncol,2013,39 (12):1309-1316. 被引量:1
  • 4Honore C,Goere D,Dartigues P,et al.Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz's tumour) of the pancreastreated with HIPEC[J].Anticancer Res,2012,32 (3):1069-1073. 被引量:1
  • 5Zaanan A,Trouilloud I,Markoutsaki T,et al.FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancerfrom the FIRGEM study[J].BMC Cancer,2014,14 (1):441-445. 被引量:1
  • 6Tentes AA,Kyziridis D,Kakolyris S,et al.Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectablepancreatic cancer[J].Gastroenterol Res Pract,2012,27 (6):1065-1071. 被引量:1
  • 7Tschoep-Lechner KE,Milani V,Berger F,et al.Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer[J].Int J Hyperthermia,2013,29(1):8-16. 被引量:1
  • 8楼建,吴敏华.热化疗在恶性肿瘤治疗中的应用[J].中国医师杂志,2012,14增刊:198-199. 被引量:1
  • 9Siegel R, Ma J, Zou ZH, et al. Cancer Statistics,2014[ J]. CA Cancer J Clin, 2014, 64(1): 9-29. 被引量:1
  • 10Wolfgang CL, Herman JM, Laheru DA, et al. Recent Progress in Pancreatic Cancer[J]. CA Cancer J Clin, 2013, 63 (5): 318-348. 被引量:1

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部